Table 2.

A brief list of the top master regulators predicted to be activated or inhibited (|z-value|> 2.0) for the five WGCNA modules which are associated with the HOT lesions.

Module ID (color)	Highly activated master regulator (z-score)	Highly inhibited master regulator (z-score)
WM2 (lightgreen)	NMK1/2 (4.123), MYC (3.873), MYCN (2.828), and MLXIPL (2.646)	chemical drug interventions: 5-fluorouracil (− 2.714), ST1926 (− 2.828), sirolimus (rapamycin) (− 3), SGI-1776 (− 4)
WM5 (cyan)	coagulation factor II thrombin receptor (F2R/PAR1) (3.357), integrin beta-4 (ITGB4) (3.266), fibroblast growth factor receptor 2 (FGFR2) (3.162), and SRSF protein kinase 1 (SRPK1) (2.714)	chemical drug interventions: imatinib (− 2.837), emodin (− 2.887), lovastatin (− 2.982), AEE788 (− 3), sitravatinib (− 3.441), and 3D185 (− 4.243)
WM6 (tan)	endothelin-1(EDN1) (3.182), NADPH oxidase 4 (NOX4) (3.051), apoptosis-antagonizing transcription factor (AATF) (2.828), and Vegf (group) (2.475)	SD-1008 intervention (− 2.502) and synaptic functional regulator FMR1 (FMR1) (− 3)
WM11 (red)	solute carrier family 2, facilitated glucose transporter member 4 (SLC2A4) (3.742), bone morphogenetic protein 1 (Type 1 BMP1) (3.402), activin receptor-like kinase 1 (ACTVRL1) (2.828) and insulin receptor (INSR) (2.646)	inositol hexakisphosphate kinase 2 (IP6K2) (− 2.746), mTORC1 (complex) (− 2.921)
WM20 (darkgrey	p21-activated kinase 2 (PAK2) (2.333), nuclear factor, erythroid 2 like 2 (NFE2L2) (2.236) and 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) (2.121)	N/A